Navigation Links
Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839

LOUISVILLE, Colo., June 26, 2007 /PRNewswire-FirstCall/ -- Replidyne, Inc. today announced results from three Phase I trials studying REP8839, a novel topical antibiotic that has shown potent in vitro activity against major skin pathogens including methicillin-resistant S. aureus (MRSA). The results of the Phase I trials show that topically applied REP8839 appears safe, well-tolerated and associated with low systemic exposure, or drug absorption into the bloodstream, which is desirable for a topical antibiotic treatment. Based on these results, Replidyne plans to initiate Phase II trials in children with impetigo, the most common bacterial skin infection, by the end of the year.

"REP8839 is a promising development candidate and has the potential to be an important treatment option for physicians in the ongoing fight against drug-resistant infections including MRSA, a growing public health concern," said Kenneth J. Collins, Replidyne's President and Chief Executive Officer. "With these safety data, we intend to move forward into Phase II trials to study the safety and efficacy of REP8839 in patients with impetigo and other skin and wound infections."

REP8839 was tested in three Phase I trials which collectively enrolled over 400 subjects. In the first Phase I trial, safety, tolerability and skin irritancy were tested following repeated daily application of REP8839, at three drug concentrations (1%, 2% and 4%), on intact and abraded skin. Irritancy scores comparable to placebo were recorded for all REP8839 exposed test subjects. In the second study, in addition to safety, tolerability and dermal irritancy, systemic exposure was examined following repeated daily application of REP8839 on a larger surface area of intact and abraded skin. In all subjects, REP8839 was associated with low systemic exposure and low skin irritancy. In the third study, a 2% formulation of REP8839 was tested for its ability
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Replidyne Phase II Pediatric Trial Meets Primary Objective
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com announces ... available in its catalogue: Needle-Free ... http://www.reportlinker.com/p02332847/Needle-Free-Delivery-Technology-and-Market-Forecast-2014-2024.html ... technological and commercial prospects What does the ... Visiongain,s brand new report shows you the ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire-iReach/ -- CountryFocus: ... Poland (Photo - ... CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Poland " ... key trends in the healthcare market and provides ... healthcare infrastructure. Most importantly, the report provides valuable ...
(Date:8/28/2014)... 2014  Decision Resources Group finds that the market for ... billion by 2023 in the United States ... , Italy , Spain ... Japan . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin ... by the launch of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, ...
Breaking Medicine Technology:Needle-Free Delivery: Technology and Market Forecast 2014-2024 2Needle-Free Delivery: Technology and Market Forecast 2014-2024 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 4Needle-Free Delivery: Technology and Market Forecast 2014-2024 5Needle-Free Delivery: Technology and Market Forecast 2014-2024 6Needle-Free Delivery: Technology and Market Forecast 2014-2024 7Needle-Free Delivery: Technology and Market Forecast 2014-2024 8Needle-Free Delivery: Technology and Market Forecast 2014-2024 9Needle-Free Delivery: Technology and Market Forecast 2014-2024 10Needle-Free Delivery: Technology and Market Forecast 2014-2024 11Needle-Free Delivery: Technology and Market Forecast 2014-2024 12Needle-Free Delivery: Technology and Market Forecast 2014-2024 13Needle-Free Delivery: Technology and Market Forecast 2014-2024 14Needle-Free Delivery: Technology and Market Forecast 2014-2024 15Needle-Free Delivery: Technology and Market Forecast 2014-2024 16Needle-Free Delivery: Technology and Market Forecast 2014-2024 17Needle-Free Delivery: Technology and Market Forecast 2014-2024 18Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2
... Reportlinker.com announces that a new market ... , US Orthopedic Devices Market ... , http://www.reportlinker.com/p0158872/US-Orthopedic-Devices-Market-Analysis--Forecasts-to-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , ... to 2015 , Summary , ...
... EF Johnson Technologies, Inc. (Nasdaq: EFJI ), a leading ... for the quarter ended September 30, 2009. Revenues were ... $1.6 million, or $(0.06) per diluted share, for the three ... with our orders and contract awards, the third quarter revenue ...
Cached Medicine Technology:Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 2Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 3Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 4Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 5Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 6Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 7Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 8Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 9Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 10Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 11Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 12Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 13Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 14Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 15Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 16Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 17EF Johnson Technologies Announces Third Quarter Results 2EF Johnson Technologies Announces Third Quarter Results 3EF Johnson Technologies Announces Third Quarter Results 4EF Johnson Technologies Announces Third Quarter Results 5EF Johnson Technologies Announces Third Quarter Results 6EF Johnson Technologies Announces Third Quarter Results 7EF Johnson Technologies Announces Third Quarter Results 8
(Date:8/29/2014)... 30, 2014 Top10inaction, a professional product ... providers in the online service industry for the month ... leaders Webex, GotoMeeting and Infinite. , With over thousands ... to determine which provider is ideally a good fit ... search for compelling consumer goods and services agencies to ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... inventor from Harrisburg, Pa., had to have breast reconstruction. ... to be sub-par, so she decided that there needed ... a better look for a woman or man who ... visible, as well as promotes confidence and peace of ...
(Date:8/29/2014)... The West African Ebola outbreak took a more deadly turn ... new cases this week -- the biggest jump in infections ... Liberia, the U.N. health agency said, but cases in Guinea ... reported. "There are serious problems with case management ... "The situation is worsening in Liberia and Sierra Leone." ...
(Date:8/29/2014)... ReputationChief.Com, a well-established online reputation management firm, has ... service has been launched to help individuals and organizations ... them. , In order to make sure that the ... to its clients, ReputationChief.Com has designed the service after ... , As per the indications from the company management, ...
(Date:8/29/2014)... Los Angeles, CA (PRWEB) August 29, 2014 ... Sands DDS, is now offering mini implants to area ... replaced permanently without worries of long-term teeth shifting and ... dependability associated with full-size dental implants , their ... well as faster placement and easier recovery. Once placed, ...
Breaking Medicine News(10 mins):Health News:Top10InAction Reveals Best Web Conference Providers 2Health News:Biggest Ever Weekly Rise in Ebola Cases, U.N. Agency Says 2Health News:Biggest Ever Weekly Rise in Ebola Cases, U.N. Agency Says 3Health News:ReputationChief.Com Announces a New Service ‘Remove Bad Reviews’ 2Health News:Dental Implants Dentist, Kevin Sands DDS, Is Now Offering Mini Implants 2
... allows physicians and dentists to request disability insurance quotes, compare ... ... San Clemente, CA (PRWEB) July 31, 2008 ... disability insurance] and life insurance brokerage service, recently launched a ...
... the launch of its kidney disease education and screening program in New ... ... American Kidney Fund today announced the launch of its www.kidneyfund.org ... , , ,The American Kidney Fund,s MIKE program (Minority Intervention and Kidney ...
... containing SSRIs can interrupt dopamine levels and other hormonal levels causing ... ... (PRWEB) July 31, 2008 -- Recent trends of antidepressants being prescribed ... time high. In fact, according to a government study, antidepressants have ...
... blood drive at its Phillipsburg location on Saturday, August 9th from ... ... 31, 2008 -- Phillipsburg Easton Honda is hosting a blood drive ... 1:45PM., , , , ,"Demand for blood donations remains high, and ...
... skin tissues gives a new cellulite solution the edge to help the skin ... ... troubled and photo-damaged skin can be a frustrating part of your life. There ... scaly rashes and age spots. , , ,These ailments can be hard to ...
... Georges C. Benjamin, MD, FACP, FACEP (E), ... WASHINGTON, July 30 The American Public,Health Association ... the Family Smoking and Tobacco Control Act with ... the health of,Americans, particularly children, by giving the ...
Cached Medicine News:Health News:New Website Helps Doctors and Dentists Locate Disability Insurance 2Health News:New Website Helps Doctors and Dentists Locate Disability Insurance 3Health News:American Kidney Fund Launches Screening Program in New York City 2Health News:Lyriana Announces Antidepressants Now Linked to Declining Libido in Women 2Health News:Lyriana Announces Antidepressants Now Linked to Declining Libido in Women 3Health News:Lyriana Announces Antidepressants Now Linked to Declining Libido in Women 4Health News:Phillipsburg Easton Honda to Host Miller-Keystone Blood Drive 2Health News:Phillipsburg Easton Honda to Host Miller-Keystone Blood Drive 3Health News:New Skin Revitalizing Product Uses Naturally Occurring Serum for the Repair of Sun Damaged Skin 2Health News:New Skin Revitalizing Product Uses Naturally Occurring Serum for the Repair of Sun Damaged Skin 3
... Suture™ ENDO PADDLE RETRACT™ 12 mm instrument ... general, urologic,thoracic, colorectal and other endoscopic procedures ... stomach, or liver. , ,The ENDO ... retractor at the distal end of the ...
... Introducing the widest offering of single-use instruments ... and long 43cm lengths for Bariatric Surgery. ... , Extended insulation covers the pivot points to ... , A 4mm universal cord, which eliminates gapping ...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: